Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New indication: Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer (ANCHOR)
Study: Single-arm, multicenter, Phase-2 trial Previosly untreated, BRAF V600E mutant CRC Encorafenib + Binimetinib + Cetuximab q28 (n=95) Efficacy: ORR: 47.4% [37.0-57.9] mPFS: 5.8 mos [4.6-6.6 mos] mOS: 18.3 mos
New Drug: Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Study: Phase I-II, nonrandomized, open-label trial Pretreated metastatic colorectal cancer patients with KRAS G12C mutation Adagrasib + Cetuximab (n=32) and Adagrasib (n=44) Efficacy: mOS: 13.4 [9.5-20.1] and 19.8 mos [13.5-20.8]